Page 1

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update ● CUREVAC ● Strategic focusing on second - generation mRNA program jointly developed with GSK after withdrawal of first - generation COVID - 19 vaccine candidate , CVnCoV , from regulatory review ● the RNA people ● Nature publication of promising pre - clinical results for second - generation COVID - 19 vaccine candidate , CV2CoV , in study with Harvard Medical School , showing comparable immune response to a licensed mRNA vaccine Positive developments across rest of the pipeline , including pre - clinical results in molecular therapies and progress of Phase 1 study with lead candidate in oncology Re - allocation of existing manufacturing lines and capacities to support second - generation program and streamlining of external manufacturing network Cash position of € 1.06 billion as of September 30 , 2021. CureVac continues to assess supplier commitments related to the withdrawal of first - generation COVID - 19 vaccine candidate CureVac will host a webcast and conference call on Friday , November 19 , 2021 , at 8 a.m. EST / 2 p.m. CET . Webcast and conference call information are provided in the press release TÜBINGEN , Germany / BOSTON , USA - November 18 , 2021 – CureVac N.V. ( Nasdaq : CVAC ) , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ( " mRNA " ) , today announced financial results for the third quarter and first nine months of 2021 and provided a business update . " As the global fight against SARS - CoV - 2 continues , we are focused on creating a new generation of vaccines while building CureVac's position as a leading player in the mRNA space , " said Franz - Werner Haas , Chief Executive Officer of CureVac . " The strategic decision to withdraw our first - generation COVID - 19 candidate , CVnCoV , enables us to accelerate our second - generation program in partnership with GSK . Together , we are advancing our technology platform to deliver a suite of innovative mRNA vaccines in infectious diseases , including an endemic COVID - 19 vaccine with the goal to address evolving market demands as the world transitions from the current pandemic to an endemic COVID 19 environment . Learnings from the first - generation program are not only expected to support the second - generation program but will also be leveraged for our programs in oncology and protein therapies . " " Following the withdrawal of CVnCoV , we now aim to refocus our existing contractual commitments on our second - generation vaccine program , " said Pierre Kemula , Chief Financial Officer of CureVac . " Over the last 18 months , we aimed to balance our significant COVID - 19 financial exposure with upfront payments such as in the European APA as well as revenues from collaborations and grants . Looking forward , we will continue to run our operations with financial discipline . "